Aspergillus is a ubiquitous genus of filamentous fungi that produces airborne conidia (asexual spores) constantly inhaled by humans. While immunocompetent individuals clear these spores via innate immune mechanisms, immunocompromised states allow germination into invasive hyphae that penetrate blood vessels, causing tissue necrosis and disseminated infection. Aspergillus fumigatus accounts for approximately 90% of human aspergillosis cases, manifesting across a spectrum from allergic reactions (ABPA) to life-threatening invasive disease.
Imagine Aspergillus spores as microscopic parachutists constantly landing in your lungs β hundreds of them every day. In a healthy person, the lung's security team (alveolar macrophages and neutrophils) immediately arrests and destroys these invaders before they can even unpack their gear. But when your immune system is weakened β imagine the security guards are sleeping (from corticosteroids), understaffed (neutropenia), or distracted (HIV) β the parachutists have time to germinate. They sprout long invasive filaments (hyphae) like roots breaking through concrete, burrowing directly into blood vessel walls. Once inside the vasculature, they spread like a weed infestation through a garden's irrigation system, blocking blood flow and causing tissue to die from lack of oxygen. In some people with allergies, these spores don't invade at all β instead, they trigger a massive overreaction, like a security team that mistakes a tourist for a terrorist and tears apart the entire building looking for them (ABPA). In old lung cavities from tuberculosis, Aspergillus can move in like squatters colonizing an abandoned building, forming a fungal ball (aspergilloma) that just sits there, sometimes bleeding.
Inhalation and Initial Defense:
- Aspergillus conidia (2-3 ΞΌm diameter) β inhaled into terminal airways and alveoli (hundreds of spores/day in normal environments)
- Alveolar macrophages β TLR2/TLR4 recognition of fungal Ξ²-glucan and galactomannan β phagocytosis of conidia
- If conidia escape macrophage clearance β begin swelling (6-8 hours) β germination into hyphae
- Neutrophil recruitment β CXCL1, CXCL2, IL-8 release β neutrophil oxidative burst (NADPH oxidase) and degranulation β hyphal killing
- Dendritic cells β Dectin-1 receptor (Ξ²-glucan recognition) β CARD9 signaling β IL-23, IL-17 production β adaptive Th1/Th17 responses
Invasive Aspergillosis Cascade (in immunocompromised states):
graph TD
A[Aspergillus conidia inhaled] --> B{Immune status}
B -->|"Neutropenia <500/ΞΌL"| C[Germination into hyphae]
B -->|High-dose corticosteroids| C
B -->|"HIV CD4+ <50"| C
B -->|Intact immunity| D[Macrophage clearance]
C --> E[Hyphal penetration of lung tissue]
E --> F[Angioinvasion via proteases]
F --> G[Vascular thrombosis]
G --> H[Tissue necrosis]
F --> I[Hematogenous dissemination]
I --> J[Brain invasion]
I --> K[Multi-organ involvement]
J --> L[Fungal meningitis/brain abscess]
K --> M["Mortality >50%"]
Molecular Invasion Mechanism:
- Aspergillus hyphae β secrete gliotoxin (immunosuppressive mycotoxin) β inhibits phagocyte NADPH oxidase
- Hyphae β produce elastase, alkaline protease β degradation of basement membrane collagen IV, elastin
- Direct angioinvasion β endothelial penetration β platelet aggregation, thrombosis β pulmonary infarction
- Galactomannan (fungal cell wall polysaccharide) β released into bloodstream β serum detection threshold >0.5 optical density index for diagnosis
Allergic Bronchopulmonary Aspergillosis (ABPA):
- Aspergillus antigens in atopic individuals β Th2 polarization β IL-4, IL-5, IL-13 production
- IgE-mediated hypersensitivity β mast cell degranulation β bronchospasm, mucus hypersecretion
- Eosinophil recruitment (IL-5) β eosinophil peroxidase-mediated tissue damage
- Aspergillus-specific IgE >0.35 kUA/L and total IgE >1000 IU/mL diagnostic criteria
- Central bronchiectasis from chronic inflammation β permanent airway damage
Biofilm Formation:
- Aspergillus hyphae β extracellular matrix production (polysaccharides, proteins, extracellular DNA)
- Biofilm β reduced antifungal penetration β minimal inhibitory concentration increases 10-1000Γ for azoles
- Fungal persistence in lung cavities or implanted medical devices
Immunocompromise as Primary Risk Factor:
Aspergillus infection is a direct barometer of immune system failure, particularly neutrophil and T-cell function. This aligns with the Selfish Immune System principle β when the immune system prioritizes energy conservation over pathogen surveillance (chronic stress, corticosteroid use, metabolic exhaustion), opportunistic fungi exploit this vulnerability. The threshold for invasive aspergillosis is typically:
- Absolute neutrophil count <500 cells/ΞΌL for >10 days (chemotherapy, aplastic anemia)
- CD4+ T-cell count <50 cells/ΞΌL (AIDS-defining illness)
- Prednisone equivalent >20 mg/day for >3 weeks (or any immunosuppressive regimen post-transplant)
Clinical Presentations Across the Spectrum:
-
Invasive Pulmonary Aspergillosis (IPA): Most common in neutropenic patients. Presents with fever unresponsive to antibiotics, pleuritic chest pain, hemoptysis. CT chest shows "halo sign" (ground-glass opacity surrounding nodule) or "air crescent sign" (late finding). Mortality 30-90% depending on host factors and treatment timing.
-
Chronic Pulmonary Aspergillosis (CPA): Colonizes pre-existing lung cavities (tuberculosis, sarcoidosis, COPD bullae). Aspergilloma (fungal ball) can erode into blood vessels β massive hemoptysis. Requires surgical resection if bleeding recurs.
-
Allergic Bronchopulmonary Aspergillosis (ABPA): Occurs in 1-2% of asthma patients, 7-10% of cystic fibrosis patients. Presents with worsening asthma control, fleeting pulmonary infiltrates, bronchiectasis. Treat with corticosteroids (paradoxically) plus antifungals to reduce fungal burden.
-
Disseminated Aspergillosis: Hematogenous spread to brain (30% of disseminated cases), skin, kidneys, heart. CNS aspergillosis β ring-enhancing lesions, hemorrhagic infarcts β mortality approaching 100% without aggressive treatment.
Evolutionary Mismatch Context:
Modern immunosuppressive therapies (corticosteroids, chemotherapy, biologics) create an evolutionary mismatch β our immune system evolved to handle occasional acute infections, not chronic pharmaceutical suppression. Aspergillus, which has coexisted with humans for millennia as a harmless environmental saprophyte, becomes lethal when we artificially disable our defenses. This is iatrogenic vulnerability.
Intervention Implications:
- Primary prevention in high-risk patients: HEPA filtration in hospital rooms (removes >99.97% of particles >0.3 ΞΌm), antifungal prophylaxis (posaconazole, voriconazole) during neutropenia
- Corticosteroid tapering: Minimize dose and duration in chronic inflammatory conditions; consider steroid-sparing agents (methotrexate, biologics)
- Immune reconstitution: Address underlying causes of immunosuppression β optimize HIV treatment (ART to suppress viral load), nutritional repletion in malnutrition, vitamin D optimization (enhances cathelicidin and Ξ²-defensin production against fungi)
- Biofilm disruption strategies: N-acetylcysteine (mucolytic, disrupts extracellular matrix), combination antifungal therapy (azole + echinocandin)
- ABPA management: High-dose corticosteroids (0.5-1 mg/kg prednisone) to suppress Th2 inflammation, itraconazole (200 mg BID) to reduce fungal antigen load, monitor total IgE (should decrease >25% if treatment effective)
Diagnostic Thresholds:
- Serum galactomannan optical density >0.5 (sensitivity 70-80% in neutropenic patients, lower in non-neutropenic)
- Bronchoalveolar lavage galactomannan >1.0 (higher sensitivity)
- (1β3)-Ξ²-D-glucan >80 pg/mL (non-specific for Aspergillus, also positive in Candida, Pneumocystis)
- Aspergillus-specific IgG >27 mg/L suggests chronic infection
- Aspergillus fumigatus causes 90% of invasive aspergillosis; A. flavus (10%), A. niger (<5%)
- Invasive aspergillosis mortality remains 30-50% even with optimal antifungal therapy (voriconazole, isavuconazole)
- Neutropenia <500 cells/ΞΌL for >10 days is the strongest single risk factor for invasive disease
- Corticosteroid-induced immunosuppression accounts for 25-30% of invasive aspergillosis cases outside oncology
- Galactomannan is a fungal cell wall polysaccharide (polymer of mannose and galactofuranose) released during active growth
- ABPA occurs in 1-2% of asthma patients and 7-10% of cystic fibrosis patients; diagnosed by Aspergillus-specific IgE >0.35 kUA/L plus total IgE >1000 IU/mL
- Aspergillus biofilms increase antifungal resistance 10-1000Γ compared to planktonic fungi
- "Halo sign" on chest CT (ground-glass opacity around nodule) indicates early IPA; "air crescent sign" (late finding) indicates healing with fungal ball retraction
- CNS aspergillosis occurs in 10-30% of disseminated cases, nearly always fatal without source control
- Environmental exposure risk highest during construction/renovation (airborne spore counts increase 100-1000Γ), composting, marijuana smoking (Aspergillus contamination of cannabis common)
- immunosuppression β severe immunosuppression (neutropenia, T-cell deficiency, corticosteroids) is prerequisite for invasive aspergillosis; Aspergillus is a sentinel organism for immune failure
- neutropenia β absolute neutrophil count <500/ΞΌL for >10 days is strongest risk factor; neutrophils provide primary defense via oxidative burst and NET formation against hyphae
- neutrophils β neutrophil NADPH oxidase produces superoxide anion and hydrogen peroxide that kill Aspergillus hyphae; genetic defects in NADPH oxidase (chronic granulomatous disease) cause recurrent aspergillosis
- alveolar macrophages β first-line defense in lungs; phagocytose and kill Aspergillus conidia via TLR2/TLR4 recognition before germination; depletion allows invasive disease
- corticosteroids β exogenous corticosteroids suppress neutrophil function, macrophage activation, and T-cell immunity; doses >20 mg prednisone equivalent/day for >3 weeks increase aspergillosis risk 5-10Γ
- cortisol β chronic hypercortisolemia (Cushing syndrome) or exogenous administration creates permissive environment for Aspergillus by suppressing NF-ΞΊB, reducing phagocyte oxidative capacity
- HIV β AIDS patients with CD4+ <50/ΞΌL at high risk for disseminated aspergillosis; often co-occurs with other opportunistic infections (Pneumocystis, CMV)
- lung β primary site of Aspergillus entry via inhaled conidia; alveolar architecture provides large surface area for spore deposition; pre-existing cavitary disease (TB, bullae) allows aspergilloma formation
- asthma β 1-2% of asthma patients develop ABPA from Th2-mediated hypersensitivity to Aspergillus antigens; worsening asthma control despite therapy should prompt ABPA evaluation
- cystic fibrosis β 7-10% of CF patients develop ABPA; thick mucus provides nutrient-rich environment for Aspergillus colonization; chronic inflammation accelerates bronchiectasis
- biofilms β Aspergillus forms extracellular matrix biofilms in lung cavities and on medical devices; biofilm structure reduces antifungal penetration 10-1000Γ, requiring combination therapy or surgical debridement
- Candida albicans β both are opportunistic fungi exploiting similar immunocompromised states; co-infections possible in transplant recipients, AIDS; share Ξ²-glucan cell wall component detected by Dectin-1
- Cryptococcus β another opportunistic fungus causing pulmonary and CNS disease in AIDS, transplant; unlike Aspergillus, Cryptococcus has polysaccharide capsule that inhibits phagocytosis
- Pneumocystis jirovecii β obligate fungal pathogen in AIDS (CD4+ <200); often co-infects with Aspergillus in severely immunocompromised; both detectable by (1β3)-Ξ²-D-glucan assay
- organ transplantation β solid organ transplant recipients (lung, heart, liver, kidney) on lifelong immunosuppression at 5-10% lifetime risk of invasive aspergillosis; lung transplant highest risk (15-25%)
- chemotherapy β myelosuppressive chemotherapy (acute leukemia induction, hematopoietic stem cell transplant conditioning) causes prolonged neutropenia; aspergillosis leading infectious cause of death in these patients
- type 2 inflammation β ABPA driven by Th2 cytokines (IL-4, IL-5, IL-13) and IgE-mediated mast cell/eosinophil activation; paradoxically requires corticosteroid treatment despite fungal infection
- TLR4 β recognizes Aspergillus cell wall components (Ξ²-glucan, galactomannan) on alveolar macrophages and neutrophils; TLR4 -> MyD88 -> NF-ΞΊB activation triggers pro-inflammatory cytokine release (TNF-Ξ±, IL-1Ξ², IL-6)
- Dectin-1 β C-type lectin receptor specific for Ξ²-1,3-glucan in fungal cell walls; Dectin-1 -> CARD9 -> NF-ΞΊB pathway critical for Th17 immunity; CARD9 deficiency causes familial susceptibility to invasive fungal infections
- IL-17 β Th17 cells produce IL-17A/F in response to Aspergillus; IL-17 recruits neutrophils via G-CSF and chemokine production; IL-17 deficiency (genetic or from biologics like secukinumab) increases aspergillosis risk
- NADPH oxidase β neutrophil enzyme complex that generates superoxide (O2-) and hydrogen peroxide (H2O2) to kill Aspergillus hyphae; chronic granulomatous disease (NADPH oxidase deficiency) causes life-threatening aspergillosis in childhood
- vitamin D β vitamin D receptor activation enhances cathelicidin (LL-37) and Ξ²-defensin-2 production in respiratory epithelium; both AMPs have anti-Aspergillus activity; vitamin D deficiency (<20 ng/mL) associated with increased invasive fungal infection risk
- Module 2 (Evolutionary Medicine Part 2 β fungal infections as opportunistic pathogens in immunocompromised states)
- Module 6 (Organs I β pulmonary aspergillosis, biofilm formation in respiratory system)
- Module 8 (Clinical Integration β Aspergillus as example of pathogen exploiting immune dysfunction)